Volume | 10,661 |
|
|||||
News | (1) | ||||||
Day High | 2.08 | Low High |
|||||
Day Low | 1.98 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
TherapeuticsMD Inc | TXMD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.98 | 1.98 | 2.08 | 2.03 | 1.98 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
277 | 10,661 | US$ 2.01 | US$ 21,417 | - | 1.84 - 4.35 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:52:08 | 1 | US$ 2.03 | USD |
TherapeuticsMD Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
21.57M | 10.58M | - | 1.3M | -10.28M | -0.97 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
TherapeuticsMD News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TXMD Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.0208 | 2.17 | 1.96 | 2.05 | 11,280 | 0.0092 | 0.46% |
1 Month | 2.13 | 2.25 | 1.96 | 2.12 | 11,372 | -0.10 | -4.69% |
3 Months | 2.36 | 2.3935 | 1.84 | 2.08 | 17,840 | -0.33 | -13.98% |
6 Months | 2.25 | 2.75 | 1.84 | 2.23 | 19,107 | -0.22 | -9.78% |
1 Year | 3.95 | 4.35 | 1.84 | 2.77 | 20,637 | -1.92 | -48.61% |
3 Years | 1.32 | 11.69 | 0.1503 | 1.02 | 2,010,088 | 0.71 | 53.79% |
5 Years | 2.56 | 11.69 | 0.1503 | 1.49 | 3,487,392 | -0.53 | -20.70% |
TherapeuticsMD Description
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates. |